Paradigm Capital Analyst Discusses First Biosynthetics Cannabis Conference 2

Paradigm Capital Analyst Discusses First Biosynthetics Cannabis Conference

Paradigm Capital Equities Analyst for Healthcare and Biotechnology, Rahul Sarugaser, discusses the company’s biosynthetics cannabis conference on April 15, the first of its kind in the industry. Sarugaser notes that while no company is producing biosynthetic cannabinoids at scale yet, biosynthetics have the potential to bring down the costs of goods. Sarugaser provides an overview of the process and the benefits of using yeast, E. coli, or algae as a chassis. While the industry has not been able to identify the best chassis yet, he suggests the best biosynthetic cannabinoids are a result of the best combination of chassis, intellectual property, and scientific team. Sarugaser highlights Ginkgo Bioworks Inc as the segment leader and notes the company’s partnership with cannabis heavyweight Cronos Group Inc (TSE:CRON) (NASDAQ:CRON) (FRA:7CI) to develop cultured cannabinoids has the potential to produce biosynthetic cannabinoids at scale.


Check out our website:



SUBSCRIBE to our YouTube:

SUBSCRIBE to our 2nd YouTube Channel – Midas Letter Clips:

SUBSCRIBE to our Newsletter:

Download Our Podcast on iTunes:


Follow Us on Twitter:

Like Us on Instagram:

Like Us on Facebook:




Leave a Comment

Your email address will not be published. Required fields are marked *



Click one of our representatives below to chat on WhatsApp or send us an email to [email protected]


× Order Via Whatsapp?